Viral Hepatitis

You have full text access to this OnlineOpen article

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response†‡

  1. Sanaa M. Kamal1,§,*,
  2. Samer S. El Kamary2,
  3. Michelle D. Shardell2,
  4. Mohamed Hashem2,
  5. Imad N. Ahmed1,2,§,
  6. Mohamed Muhammadi1,
  7. Khalifa Sayed1,
  8. Ashraf Moustafa1,
  9. Sarah Abdel Hakem1,
  10. Amany Ibrahiem1,
  11. Mohamed Moniem3,
  12. Hoda Mansour3,
  13. Mohamed Abdelaziz1

Article first published online: 17 OCT 2007

DOI: 10.1002/hep.21917

Issue

Hepatology

Hepatology

Volume 46, Issue 6, pages 1732–1740, December 2007

Additional Information

How to Cite

Kamal, S. M., El Kamary, S. S., Shardell, M. D., Hashem, M., Ahmed, I. N., Muhammadi, M., Sayed, K., Moustafa, A., Hakem, S. A., Ibrahiem, A., Moniem, M., Mansour, H. and Abdelaziz, M. (2007), Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology, 46: 1732–1740. doi: 10.1002/hep.21917

Author Information

  1. 1

    Department of Gastroenterology and Hepatology, Ain Shams University, Cairo, Egypt

  2. 2

    Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD

  3. 3

    Diagnostics and Research Institute, DIAGSERA, Cairo, Egypt

  1. §

    Beth Israel Deaconess Medical Center, Boston, MA

*Beth Israel Deaconess Medical Center, 110 Franas Street, Suite 2F, Boston, MA 02215

  1. †

    The protocol registration was NCT00277862.

  2. ‡

    Potential conflict of interest: Drs. Sayed, Abdelaziz, Mansour, Moniem, Ibrahiem, Hakem, Hashem, Kamal, and Muhammadi received grants from Schering-Plough.

Publication History

  1. Issue published online: 28 NOV 2007
  2. Article first published online: 17 OCT 2007
  3. Manuscript Accepted: 9 JUL 2007
  4. Manuscript Received: 29 MAY 2007

Funded by

  • Schering-Plough (Kenilworth, NJ)
  • Trans-European mobility scheme for university studies (TEMPUS). Grant Number: IMG 04-E.G-1096
  • International Society of Infectious Diseases (United States). Grant Number: 9641

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (251K)

References

  • 1
    Hoofnagle JH. Course and outcome of hepatitis C. HEPATOLOGY 2002; 36(5 Suppl. 1 ): S21–S29.
    Direct Link:
  • 2
    Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182: 698–707.
  • 3
    Lyra AC, Ramrakhiani S, Bacon BR, Di Bisceglie AM. Infection with hepatitis C virus genotype 4 in the United States. J Clin Gastroenterol 2004; 38: 68–71.
  • 4
    van Asten L, Verhaest I, Lamzira S, Hernandez-Aguado I, Zangerle R, Boufassa F, et al. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis 2004; 189: 292–302.
  • 5
    Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millennium: the GEMHEP GenoCII Study. J Viral Hepat 2005; 12: 405–413.
    Direct Link:
  • 6
    Koshy A, Marcellin P, Martinot M, Madda JP. Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver 2000; 20: 335–339.
    Direct Link:
  • 7
    Zylberberg H, Chaix ML, Brechot C. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med 2000; 132: 845–846.
  • 8
    Kamal SM, Madwar MA, Peters T, Fawzy R, Rasenack J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000; 32: 172–174.
  • 9
    Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 858–866.
  • 10
    Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99: 1733–1737.
    Direct Link:
  • 11
    Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, et al. Peginterferon a-2b plus ribavirin compared with interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24: 568–574.
    Direct Link:
  • 12
    El-Zayadi A-R, Attia M, Barakat EMF, Badran HM, Hamdy H, El-Tawil A, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg-interferon-a2b/ribavirin or induction-dose interferon-a2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005; 100: 2447–2452.
    Direct Link:
  • 13
    Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006; 43: 954–960.
    Direct Link:
  • 14
    Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97–103.
  • 15
    Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451–460.
  • 16
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–699.
  • 17
    Blackwelder WC. “Proving the null hypothesis” in clinical trials. Control Clin Trials 1982; 3: 345–353.
  • 18
    Agresti A, Coull BA. Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat 1998; 52: 119–126.
  • 19
    Hosmer DW. Applied Logistic Regression. 2nd ed. New York, NY: Wiley-Interscience; 2000.
  • 20
    R Development Core Team. R: a language and environment for statistical computing. Available at: http://www.R-project.org. Accessed July 2007.
  • 21
    Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2004; 20: 931–938.
    Direct Link:
  • 22
    Pearlman BL. Chronic hepatitis C therapy: changing the rules of duration. Clin Gastroenterol Hepatol 2006; 4: 963–971.
  • 23
    von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522–527.
  • 24
    Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609–2617.
  • 25
    Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. HEPATOLOGY 2004; 40: 1260–1265.
    Direct Link:
  • 26
    Yu M-L, Dai C-Y, Huang J-F, Hou N-J, Lee L-P, Hsieh M-Y, et al. A randomised study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553–559.
  • 27
    Buti M, Casado MA, Fosbrook L, Esteban R. Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1. PharmacoEconomics 2005; 23: 1043–1055.
  • 28
    Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK, for the International Hepatitis Interventional Therapy (IHIT) Group. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003; 98: 2354–2362.
    Direct Link:
  • 29
    Buti M, Casado MA, Esteban R. Therapy a la carte is more cost-effective than standard combination therapy for treatment-naive patients with chronic hepatitis C. Poster presented at: 57th Annual Meeting of the American Association for the Study of Liver Diseases; October 27-31, 2006; Boston, MA.
View Full Article (HTML) Get PDF (251K)